SAN FRANCISCO—At the May 17 California Rheumatology Alliance 10th Annual Medical and Scientific Meeting, Bevra H. Hahn, MD, professor emeritus of medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA), gave a comprehensive talk titled, 2014: An Update on Pathogenesis, Diagnosis and Treatment of SLE.
She discussed two important new clinical concepts in systemic lupus erythematosus (SLE). First was the 2012 publication of the Systemic Lupus International Collaborating Clinics (SLICC) criteria,1 which have “definite advantages,” said Dr. Hahn, due to expansion of dermatologic, neurologic and immunologic disease classification indicators. The SLICC criteria, she said, have been validated in a cohort of more than 1,700 patients with lupus and shown to have 93% specificity and 92% sensitivity. Dr. Hahn has been encouraging pharmaceutical companies to incorporate these criteria along with the older ACR SLE criteria in clinical studies going forward.